Gastric Cancer and Oligometastatic Liverinvolvement. Metastatectomy and Impact on Survival

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Offering treatment with potential to cure for participants with no such offer in today's standard treatment options, by offering metastatectomia and standard treatment with intention to cure i.e., neoadjuvant chemotherapy and gastrectomy for participants with gastric- og gastroeusofageal junction cancer. Including 20 participants from all 4 centres in Denmark able to perform the surgical procedures in question. Endpoints: 2-year overall survival.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age \> 18.

• Presence of primary T1-T4N0-N3M1 adenocarcinoma of the stomach or GEJ and max. 30% liver involvement.

• Primary tumour resectable, based on imaging workup.

• Surgical operable patients with ASA-score36 ≤ III and WHO performance status37 0-1.

• Patients eligible for treatment with systemic chemotherapy by FLOT regimen.

• Informed consent is obtained.

Locations
Other Locations
Denmark
Aarhus Univercity hospital
RECRUITING
Aarhus
Contact Information
Primary
Julie Lykke Harbjerg, MD
Juharb@rm.dk
+4520404424
Backup
Daniel Willy Kjaer, MD, PhD
dankja@rm.dk
+4551888088
Time Frame
Start Date: 2020-12-01
Estimated Completion Date: 2024-12-01
Participants
Target number of participants: 20
Treatments
Experimental: Treatment arm
Patients with oligometastatic spread form gastric og GEJ-cancer are offered standart curative treatment along with metastatectomia in the liver.
Related Therapeutic Areas
Sponsors
Collaborators: Odense University Hospital, Aalborg University Hospital, Rigshospitalet, Denmark
Leads: Aarhus University Hospital

This content was sourced from clinicaltrials.gov